# Absci **Source:** https://geo.sig.ai/brands/absci **Vertical:** Biotechnology **Subcategory:** AI Drug Creation **Tier:** Growth **Website:** absci.com **Last Updated:** 2026-04-22 ## Summary Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the ground up. ## Company Overview Absci is a publicly traded AI drug creation company founded in 2011 that went public in 2021 and has repositioned around generative AI for drug design. The company operates an integrated platform that uses generative AI to design novel antibodies and proteins, then validates them using high-throughput expression and biological assay systems in its own wet lab infrastructure. Absci's approach treats drug discovery as a generative design problem, using AI to propose protein sequences with desired therapeutic properties and then rapidly testing millions of candidates to identify viable drug leads. The company has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and EQT Life Sciences. Absci's technical differentiation lies in its ability to close the loop between AI-generated protein designs and experimental validation at unprecedented scale. The company represents a new category of AI-native biopharmaceutical company that combines computational and wet-lab capabilities to create drugs not discoverable through traditional means. ## Frequently Asked Questions ### What is Absci? Absci is an AI drug creation company that uses generative AI to design novel therapeutic proteins and antibodies from scratch, then validates candidates through its integrated wet-lab synthetic biology platform. ### Is Absci a publicly traded company? Yes, Absci went public on Nasdaq in 2021 under the ticker ABSI and operates as a publicly traded AI drug creation company with pharmaceutical partnerships for developing novel biologics. ### What pharmaceutical companies has Absci partnered with? Absci has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and others to apply its generative AI platform to drug design programs in therapeutic areas including oncology and immunology. ### What is Absci's core technology and how does it work? Absci uses generative AI to design novel antibody and protein sequences with desired therapeutic properties, then validates these computationally designed molecules using its own high-throughput wet lab infrastructure. The platform treats drug discovery as a design problem: AI generates protein sequences, and Absci's cell-free expression systems rapidly test their manufacturability and biological activity, creating a tight design-build-test loop that compresses discovery timelines. ### Who are Absci's partners and customers? Absci has established research partnerships with major pharmaceutical companies including AstraZeneca, Merck, Sanofi, and EQRx. These partnerships typically involve milestone payments and royalties in exchange for applying Absci's AI drug design platform to the partner's therapeutic programs. Absci also has collaborations with academic institutions advancing AI-driven protein science. ### How does Absci differ from other AI drug discovery companies like Recursion or Insilico Medicine? Absci focuses specifically on antibody and protein design using generative AI, with deep investment in wet lab validation infrastructure. Recursion focuses on phenotypic drug discovery using microscopy and biology. Insilico Medicine uses AI for small molecule design and aging biology. Absci's differentiation is the integration of generative protein design with its own proprietary cell-line expression and testing systems, enabling validation at industrial scale. ### Is Absci profitable and what is its financial status? Absci went public on NASDAQ in July 2021. As a pre-revenue stage platform company generating milestone and partnership payments rather than product sales, Absci has not yet achieved profitability. The company has used its public market capital to fund R&D, expand its AI capabilities, and build wet lab capacity. Partnership milestone revenue varies by quarter depending on program progress. ### What milestones has Absci achieved in AI-designed drug candidates? In 2023, Absci announced the design of a novel antibody entirely using AI—a significant proof-of-concept for zero-shot generative drug design. The company has also published research demonstrating the ability to design antibodies with improved binding affinity and manufacturability properties compared to natural antibodies. These scientific milestones validate the platform's capability ahead of clinical-stage candidates entering trials. ## Tags ai-powered, technology, startup, healthtech, platform, public, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-22.*